相关实验视频
Updated: Jun 28, 2025

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
前列腺癌的临床特征通过多基因风险评分
Christina Spears1,2, Menglin Xu3, Abigail Shoben4
1Division of Human Genetics, Department of Internal Medicine, College of Medicine, The Ohio State University, 2012 Kenny Road, Columbus, OH, 43212, USA. Christina.spears@osumc.edu.
多基因风险评分 (PRS) 显示了个性化前列腺癌查的潜力. 较高的PRS与早期诊断和家族史有关,但不是瘤等级. 对于临床使用,需要进一步的研究.
科学领域:
- 遗传学 是一个遗传学.
- 在瘤学瘤学.
- 流行病学 流行病学
背景情况:
- 全基因组关联研究确定了290多种与前列腺癌相关的单核酸变体 (SNV).
- 多基因风险评分 (PRS) 将这些SNV结合起来,以估计一个人的前列腺癌风险.
- PRS可以实现个性化查和改善结果,但需要进一步的研究来实现临床整合.
研究的目的:
- 调查前列腺癌患者中PRS和临床因素之间的关联.
- 分析PRS和诊断时的年龄,转移,组织学,ISUP等级组和家族史之间的关系.
- 考虑已知前列腺癌基因的生殖基因检测结果.
主要方法:
- 对250名欧洲血统的前列腺癌患者进行了定量回顾性图表审查.
- 患者在俄俄州立大学的生殖泌尿癌遗传学诊所接受了遗传咨询.
- 通过Ambry Genetics获得的72-SNV PRS被使用.
主要成果:
- 较高的PRS与诊断时年龄较小显著相关 (p=0.002).
- 更高的PRS与更低的转移频率相关 (p=0.006).
- 较高的PRS与前列腺癌家族史相关 (一级亲属,p=0.024).
- 没有发现PRS和ISUP等级组,组织学或二度亲属史之间的显著关联.
结论:
- 更高的PRS与前列腺癌患者的特定临床特征有关.
- 研究结果表明,PRS可以识别早期发病或家族倾向的个体.
- 更大的,多祖先的研究是必要的,以验证PRS在不同人群中的临床效用.
更多相关视频
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
07:34Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
Published on: November 17, 2023
相关概念视频
Polygenic Traits
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Cancer Prevention
Some...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer Survival Analysis